...
首页> 外文期刊>Journal of biomedical materials research. Part B, Applied biomaterials. >In vitro characteristics of a gelling PEGDA-QT polymer system with model drug release for cerebral aneurysm embolization
【24h】

In vitro characteristics of a gelling PEGDA-QT polymer system with model drug release for cerebral aneurysm embolization

机译:具有模型药物释放功能的凝胶化PEGDA-QT聚合物系统的体外特性,用于脑动脉瘤栓塞

获取原文
获取原文并翻译 | 示例
           

摘要

A liquid-to-solid gelling polymer system, such as the poly(ethylene glycol) diacrylate-pentaerythritol tetrakis (3-mercaptopropionate) (PEGDA-QT) system, can fill cerebral aneurysms more completely than current embolization materials, reducing the likelihood of aneurysm recurrence. PEGDA-QT gels were formulated using PEGDA of different molecular weights (PEGDA575 and PEGDA 700), and their characteristics were examined in vitro. Experiments examined gel time, mass change, crosslink integrity, cytotoxicity, and protein release capabilities. In general, PEGDA575-QT gels were more hydrophobic, requiring an initiating solution with a higher pH (pH 9.5) to achieve a gel time comparable to PEGDA700-QT gels, which used an initiating solution at pH 9.19. The mass change and crosslink integrity of gels were analyzed over time after gels were submerged in 150 mM phosphate buffered saline. After 380 days, PEGDA575-QT gels achieved a maximum mass increase of 72% due to water uptake, while PEGDA700-QT gels doubled their initial mass (100% increase) by 165 days. Compression tests showed that PEGDA700-QT gels hydrolyzed more quickly than PEGDA575-QT gels. Cytotoxicity assays showed that in general, PEGDA575-QT negatively affected cell growth, while PEGDA700-QT gels promoted cell viability. Sustained, controlled release of lysozyme, a 14.3 kDa protein, was achieved over an 8-week period when loaded into PEGDA700-QT gels, but PEGDA575-QT gels did not show sustained release. These studies show that although they are similar in composition, these PEGDA-QT gel formulations behave considerably differently. Although PEGDA700-QT gels swell more and degrade faster than PEGDA575-QT gels, their cytocompatibility and protein release characteristics may prove to be more beneficial for in vivo aneurysm treatment.
机译:液-固胶凝聚合物系统,例如聚(乙二醇)二丙烯酸酯-季戊四醇四(3-巯基丙酸酯)(PEGDA-QT)系统,可以比目前的栓塞材料更完全地填充脑动脉瘤,从而降低了动脉瘤的可能性复发。使用不同分子量的PEGDA(PEGDA575和PEGDA 700)配制PEGDA-QT凝胶,并在体外检查其特性。实验检查了凝胶时间,质量变化,交联完整性,细胞毒性和蛋白质释放能力。通常,PEGDA575-QT凝胶具有更大的疏水性,因此需要与具有pH 9.19的起始溶液的PEGDA700-QT凝胶相比,具有更高pH(pH 9.5)的起始溶液才能达到凝胶时间。将凝胶浸入150 mM磷酸盐缓冲盐水中后,随时间分析凝胶的质量变化和交联完整性。 380天后,由于吸水,PEGDA575-QT凝胶的最大质量增加了72%,而PEGDA700-QT凝胶的初始质量增加了165天,是其初始质量的两倍(增加100%)。压缩测试表明,PEGDA700-QT凝胶比PEGDA575-QT凝胶水解得更快。细胞毒性测定表明,一般而言,PEGDA575-QT会对细胞生长产生负面影响,而PEGDA700-QT凝胶则可促进细胞活力。当加载到PEGDA700-QT凝胶中时,在8周内实现了溶菌酶(一种14.3 kDa蛋白质)的持续控制释放,但PEGDA575-QT凝胶未显示出持续释放。这些研究表明,尽管它们的成分相似,但这些PEGDA-QT凝胶制剂的行为却大不相同。尽管PEGDA700-QT凝胶比PEGDA575-QT凝胶溶胀和降解更快,但它们的细胞相容性和蛋白质释放特性可能证明对体内动脉瘤治疗更有利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号